We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session

Clinical track: Upper GI (oesophagus, stomach, pancreas, liver)
Poster
Clinical
00:00 - 00:00
Chemoradiation-induced intratumoral immune microenvironment changes in oesophageal cancer
PO-1034
00:00 - 00:00
GemOx with low-dose RT and SBRT for locally advanced pancreatic cancer: a prospective trial
PO-1047
00:00 - 00:00
Postoperative hypofractionated Image-Guided IMRT concomitant to chemotherapy in biliary tract cancer
PO-1044
00:00 - 00:00
SBRT in liver cancer versus TACE. A prospective, non-randomised observational trial (HERACLES)
PO-1050
00:00 - 00:00
Central hepatobiliary toxicity after liver SBRT and hypo-fractionated Radiotherapy
PO-1035
00:00 - 00:00
Biliary tract tumors: the role of chemoradiotherapy – a review of the last 10 years
PO-1049
00:00 - 00:00
Treatment outcomes of liver metastasis treated with stereotactic body radiotherapy
PO-1046
00:00 - 00:00
SBRT vs conventionally fractionated radio-chemotherapy for pancreatic cancer: a case-control study
PO-1042
00:00 - 00:00
Postoperative complications and margins status after neoadjuvant SBRT for pancreatic cancer
PO-1048
00:00 - 00:00
Addition of SBRT following TACE is associated with a survival benefit in Hepatocellular Carcinoma
PO-1045
00:00 - 00:00
Analysis of serum pancreatic exocrine enzyme after radiotherapy for pancreatic carcinoma
PO-1036
00:00 - 00:00
Robotic radiosurgery treatment in HCC with PVT: Interim analysis of a prospective study
PO-1038
00:00 - 00:00
Gender disparity in esophageal cancer -- a nationwide propensity score-matched study
PO-1041
00:00 - 00:00
A new nodal delineation protocol for upper third oesophageal cancers in the SCOPE 2 trial
PO-1037
00:00 - 00:00
Reduction ratio of tumor volume is predictive factor in esophageal carcinoma undergoing SMART
PO-1043
00:00 - 00:00
Lymphopenia and worse OS are associated with GTV and fraction in patients with HCC treated with EBRT
PO-1039
00:00 - 00:00
Peritreatment peripheral blood cells predict progression hazard in esophageal cancer after treatment
PO-1040
00:00 - 00:00
Effect of surgery in locally advanced esophageal cancer after chemoradiotherapy
PO-1070
00:00 - 00:00
Hypofractionated radiotherapy for unresectable esophagus-gastric carcinoma in elderly patients
PO-1054
00:00 - 00:00
Prognostic value of CA19-9 in patients with pancreatic adenocarcinoma after chemoradiotherapy
PO-1071
00:00 - 00:00
Stereotactic radiotherapy in liver metastases of mesenchymal malignancies: role of patient selection
PO-1072
00:00 - 00:00
Dosimetric Predictors of Survival in Esophageal Cancers Treated with Preoperative Chemoradiation
PO-1073
00:00 - 00:00
Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer.
PO-1074
00:00 - 00:00
Simultaneous integrated boost concepts in radiotherapy for esophageal cancer: outcomes and toxicity
PO-1075
00:00 - 00:00
Recursive partitioning model based analysis for oligometastatic colorectal cancer treated with SBRT
PO-1055
00:00 - 00:00
Carbon-ion radiotherapy for hepatocellular carcinoma with vascular invasion
PO-1077
00:00 - 00:00
Long survivors’ nature of pancreatic cancer treated with chemoradiotherapy using photon or proton
PO-1078
00:00 - 00:00
Chemoradiation for esophageal cancer using carboplatin and paclitaxel: A single centre experience
PO-1056
00:00 - 00:00
Influence of brachytherapy on local control of locally advanced esophageal carcinomas
PO-1057
00:00 - 00:00
Proton beam therapy for hepatocellular carcinoma of caudate lobe
PO-1058
00:00 - 00:00
Definite chemo-radiotherapy with dose-escalation to patients with esophageal cancer
PO-1059
00:00 - 00:00
Cyberknife SBRT for liver metastases in heavily pre-treated patients
PO-1060
00:00 - 00:00
Stereotactic body radiotherapy for adrenal metastases of oligometastatic or oligoprogressive tumors
PO-1061
00:00 - 00:00
Role of radiotherapy in resected R0/R+ pancreatic cancer: real life single institution experience.
PO-1051
00:00 - 00:00
Stereotactic body radiotherapy can delay polymetastatic conversion in liver oligometastatic patients
PO-1062
00:00 - 00:00
Do we need a PTV around the boost in simultaneously integrated boost approaches of abdominal tumors?
PO-1063
00:00 - 00:00
Pancreatic cancer SBRT: reaching consensus in a national survey by AIRO Gastrointestinal Group
PO-1064
00:00 - 00:00
Adjuvant chemoradiation (CRT) for gastric cancer: toxicity profile and outcome in Albanian patients
PO-1065
00:00 - 00:00
Hypofractionated VMAT for Fragile Patients with Oesophageal Cancer
PO-1052
00:00 - 00:00
Clinical results of stereotactic body radiotherapy for elderly hepatocellular carcinoma patients
PO-1066
00:00 - 00:00
Outcomes of combined modality treatment in resectable esophageal carcinoma patients
PO-1067
00:00 - 00:00
How much lower dose is enough for SBRT in hepatocellular carcinoma considering normal liver?
PO-1068
00:00 - 00:00
Involved-field radiation therapy for treatment of locally advanced pancreatic adenocarcinomas.
PO-1053
00:00 - 00:00
SBRT in Hepatocellular Carcinoma: impact of dose regimen and treatment sequence
PO-1069